Edesa Biotech (EDSA) Income towards Parent Company (2013 - 2026)

Edesa Biotech has reported Income towards Parent Company for 13 years, with the latest figure at -$2.4 million in Q4 2025.

• Quarterly Income towards Parent Company fell 22.24% year-over-year to -$2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.2 million (down 23.72% YoY) and the FY2025 annual result came in at -$7.4 million, down 16.92% from the prior year.
• Income towards Parent Company retreated to -$2.4 million in Q4 2025 per EDSA's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $1.8 million in Q3 2022 and troughed at -$5.8 million in Q2 2022.
• A 5-year average of -$2.5 million and a median of -$2.2 million in 2021 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company jumped 1330.9% in 2022, then tumbled 212.08% in 2023.
• Over 5 years, Income towards Parent Company stood at -$5.3 million in 2021, then grew by 21.93% to -$4.1 million in 2022, then climbed by 15.44% to -$3.5 million in 2023, then jumped by 42.43% to -$2.0 million in 2024, then slipped by 22.24% to -$2.4 million in 2025.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$2.4 million, -$2.4 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.